These findings position ACC1 as a promising metabolic target for improving adoptive Treg therapies in autoimmune diseases and graft rejection, offering new strategies to enhance the effectiveness of Treg-based immunotherapies. The gene discussed is ACACA; the disease is autoimmune disease.